• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Erratum: Insights into the Antibacterial Mechanism of PEGylated Nano-Bacitracin A Against Streptococcus pneumonia: Both Penicillin-Sensitive and Penicillin-Resistant Strains [Corrigendum].

出版信息

Int J Nanomedicine. 2022 Jun 29;17:2807-2808. doi: 10.2147/IJN.S376407. eCollection 2022.

DOI:10.2147/IJN.S376407
PMID:35791308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9250772/
Abstract

[This corrects the article DOI: 10.2147/IJN.S178596.].

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc78/9250772/7f8d11039ffd/IJN-17-2807-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc78/9250772/301b67072d34/IJN-17-2807-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc78/9250772/7f8d11039ffd/IJN-17-2807-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc78/9250772/301b67072d34/IJN-17-2807-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc78/9250772/7f8d11039ffd/IJN-17-2807-g0002.jpg

相似文献

1
Erratum: Insights into the Antibacterial Mechanism of PEGylated Nano-Bacitracin A Against Streptococcus pneumonia: Both Penicillin-Sensitive and Penicillin-Resistant Strains [Corrigendum].
Int J Nanomedicine. 2022 Jun 29;17:2807-2808. doi: 10.2147/IJN.S376407. eCollection 2022.
2
Insights into the antibacterial mechanism of PEGylated nano-bacitracin A against : both penicillin-sensitive and penicillin-resistant strains.聚乙二醇化纳米杆菌肽 A 对青霉素敏感和青霉素耐药菌株的抗菌机制的研究。
Int J Nanomedicine. 2018 Oct 10;13:6297-6309. doi: 10.2147/IJN.S178596. eCollection 2018.
3
Erratum: Insights into the antibacterial mechanism of PEGylated nano-bacitracin A against : both penicillin-sensitive and penicillin-resistant strains [Corrigendum].勘误：聚乙二醇化纳米杆菌肽A对青霉素敏感和耐药菌株抗菌机制的见解[勘误]
Int J Nanomedicine. 2019 Jan 4;14:337. doi: 10.2147/IJN.S197963. eCollection 2019.
4
Brain-targeted delivery of PEGylated nano-bacitracin A against Penicillin-sensitive and -resistant Pneumococcal meningitis: formulated with RVG and Pluronic P85 unimers.载紫杉醇聚乙二醇纳米粒靶向递药治疗青霉素敏感和耐药性肺炎球菌性脑膜炎：用 RVG 和 Pluronic P85 两亲嵌段共聚物制剂。
Drug Deliv. 2018 Nov;25(1):1886-1897. doi: 10.1080/10717544.2018.1486473.
5
Erratum: Synthesis, Construction, and Evaluation of Self-Assembled Nano-Bacitracin a as an Efficient Antibacterial Agent in vitro and in vivo [Corrigendum].勘误：自组装纳米杆菌肽a作为一种高效抗菌剂的体外和体内合成、构建及评价[勘误]
Int J Nanomedicine. 2020 Jul 2;15:4753. doi: 10.2147/IJN.S267460. eCollection 2020.
6
PEGylated Self-Assembled Nano-Bacitracin A: Probing the Antibacterial Mechanism and Real-Time Tracing of Target Delivery in Vivo.聚乙二醇化自组装纳米杆菌肽 A：体内抗菌机制的探究和靶向递药的实时示踪。
ACS Appl Mater Interfaces. 2018 Apr 4;10(13):10688-10705. doi: 10.1021/acsami.8b00135. Epub 2018 Mar 21.
7
Erratum: Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin [Corrigendum].勘误：聚乙二醇化脂质体阿霉素诱导的手足综合征中活性氧介导的炎症和凋亡 [勘误]
Int J Nanomedicine. 2021 Dec 24;16:8335-8336. doi: 10.2147/IJN.S354929. eCollection 2021.
8
Erratum: Combined Molybdenum Gelatine Methacrylate Injectable Nano-Hydrogel Effective Against Diabetic Bone Regeneration [Corrigendum].勘误：联合钼明胶甲基丙烯酸酯可注射纳米水凝胶对糖尿病性骨再生有效 [勘误]
Int J Nanomedicine. 2023 Dec 5;18:7205-7208. doi: 10.2147/IJN.S452165. eCollection 2023.
9
Erratum: Synthesis, construction, and evaluation of self-assembled nano-bacitracin A as an efficient antibacterial agent in vitro and in vivo [Corrigendum].勘误：自组装纳米杆菌肽A作为一种高效抗菌剂的体外和体内合成、构建及评价[更正]
Int J Nanomedicine. 2019 Jan 23;14:771. doi: 10.2147/IJN.S201516. eCollection 2019.
10
[Problems with identification of beta-hemolytic streptococcus resistant to bacitracin isolated from patients with pharyngitis].[从咽炎患者中分离出的对杆菌肽耐药的β-溶血性链球菌的鉴定问题]
Med Dosw Mikrobiol. 2012;64(1):1-10.